Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142640 | 0.89 | MAPT (0.72) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL9129183 | 0.89 | MAPT (0.58) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL1918267 | 0.88 | MAPK14 (0.55) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL30838899 | 0.87 | TDP1 (0.49) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL490119 | 0.86 | AKR1B1 (0.58) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL86392 | 0.83 | MAPT (0.67) | TDP1MAPTALDH1A1RAB9APKM | |
| SCHEMBL29375440 | 0.83 | MAPT (0.67) | TDP1MAPTALDH1A1RAB9APKM | |
| SCHEMBL11575984 | 0.81 | MAPK14 (0.60) | TDP1MAPTALDH1A1RAB9APKM | |
| SCHEMBL10922670 | 0.81 | ALDH1A1 (0.54) | TDP1MAPTALDH1A1RAB9APKM | |
| SCHEMBL10917991 | 0.81 | AKR1B1 (0.53) | TDP1MAPTALDH1A1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0069810-B1 | NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS | MERCK & CO. INC. (US) | 1986-12-03 | — | — | EP | claimed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0351887-B1 | Tricyclic aromatic compounds | WELLCOME FOUND (GB) | 1995-07-26 | — | — | EP | disclosed |
| US-5395610-A | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | BURROUGHS-WELLCOME CO. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5300282-A | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | BURROUGHS-WELLCOME COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0409406-B1 | ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-08 | — | — | EP | disclosed |
| EP-0487502-A2 | Pharmaceutically active aryl-substituted amine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-27 | — | — | EP | disclosed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | disclosed |
| US-4923892-A | DOXEPIN DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0214779-B1 | TRICYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0351887-A1 | Tricyclic aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-24 | — | — | EP | disclosed |
| US-4871865-A | ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0316022-A2 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-17 | — | — | EP | disclosed |
| EP-0214779-A1 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-18 | — | — | EP | disclosed |
| EP-0069810-B1 | NOVEL DIBENZOXEPINS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THE USE OF DIBENZOXEPINS IN THE TREATMENT OF ALLERGIC CONDITIONS | MERCK & CO. INC. (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0069810-A1 | Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4282365-A | Dibenz[b,e]oxepin compounds | MERCK & CO., INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | TDP1 3993/4885L3MBTL1 1403/4885MAPT 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.